TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer-Reference-Cited by-同舟云学术

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

Published:2018 Issue:4 Volume:3 Page:e000403
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Borelli Beatrice,Moretto Roberto,Lonardi Sara,Bonetti Andrea,Antoniotti Carlotta,Pietrantonio Filippo,Masi Gianluca,Burgio Valentina,Marmorino Federica,Salvatore Lisa,Rossini Daniele,Zaniboni Alberto,Zucchelli Gemma,Martignetti Angelo,Di Battista Monica,Pella Nicoletta,Passardi Alessandro,Boccaccino Alessandra,Leone Francesco,Colombo Camilla,Granetto Cristina,Vannini Francesca,Marsico Valentina Angela,Martinelli Erika,Antonuzzo Lorenzo,Vitello Stefano,Delliponti Laura,Boni Luca,Cremolini Chiara,Falcone Alfredo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. First-line chemotherapy for mCRC—a review and evidence-based algorithm;Cremolini;Nat Rev Clin Oncol,2015

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

3. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

4. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study;Frontiers in Oncology;2024-04-04

2. Drug Combination Therapy for RAS-related Colorectal Cancer;PROG BIOCHEM BIOPHYS;2023

3. Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial);Clinical Colorectal Cancer;2023-06

4. Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance;Treatment Landscape of Targeted Therapies in Oncology;2023

5. Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer;Anti-Cancer Drugs;2022-11-15